Format

Send to:

Choose Destination
See comment in PubMed Commons below
Int J Oncol. 2012 Dec;41(6):1943-9. doi: 10.3892/ijo.2012.1653. Epub 2012 Oct 4.

Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC.

Author information

  • 1Department of Tissue Engineering, Nicolaus Copernicus University, Bydgoszcz, Poland. tomaszkloskowski@op.pl

Abstract

Lung cancer is one of the most common tumors and its treatment is still inefficient. In our previous work we proved that ciprofloxacin has a different influence on five cancer cell lines. Here, we aimed to compare the biological effect of ciprofloxacin on cell lines representing different responses after treatment, thus A549 was chosen as a sensitive model, C6 and B16 as highly resistant. Three different cell lines were analyzed (A549, B16 and C6). The characterization of continuous cell growth was analyzed with the Real-Time Cell Analyzer (RTCA)-DP system. Cytoskeletal changes were demonstrated using immunofluorescence. The cell cycle was analyzed using flow cytometry. Ciprofloxacin was cytostatic only against the A549 cell line. In the case of other tested cell lines a cytostatic effect was not observed. Cytoskeletal analysis confirms the results obtained with RTCA-DP. A549 cells were inhibited in the G2/M phase suggesting a mechanism related to topoisomerase II inhibition. The biological effects of ciprofloxacin support the hypothesis that this drug can serve as an adjuvant treatment for lung cancer, due to its properties enabling topoisomerase II inhibition.

PMID:
23042104
[PubMed - indexed for MEDLINE]
PMCID:
PMC3583647
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Spandidos Publications Icon for PubMed Central
    Loading ...
    Write to the Help Desk